Related Experiment Video
Updated: Jun 17, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
[Diffuse intrinsic brain stem glioma in children: current treatment and future directions]
P Leblond1, M Vinchon, V Bernier-Chastagner
1Unité d'oncologie pédiatrique, centre Oscar-Lambret, 59020 Lille cedex, France. p-leblond@o-lambret.fr
Abstract:
Despite the numerous clinical trials undertaken, the prognosis of children with diffuse brain stem glioma remains very poor. This review examines the different strategies for the treatment of malignant brain stem glioma such as radiation therapy, concurrent radiochemotherapy, and classical cytotoxic drugs, with a particular focus on the novel targeted and antiangiogenic drugs recently introduced in pediatric oncology. The strategy using integrin inhibitors is discussed.
Insights
Pediatric diffuse brain stem glioma has a poor prognosis. This review explores current and novel treatments, including targeted therapies and integrin inhibitors, for malignant brain stem glioma in children.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Clinical Therapeutics
Context:
- Diffuse brain stem glioma in children presents a significant clinical challenge with limited treatment options.
- Existing therapeutic strategies, including radiation and chemotherapy, offer poor long-term outcomes for pediatric patients.
- The need for innovative treatment approaches is critical due to the aggressive nature of this disease.
Purpose:
- To review established and emerging treatment modalities for malignant brain stem glioma in pediatric patients.
- To highlight the potential of novel targeted and antiangiogenic drugs in pediatric oncology.
- To specifically discuss the role of integrin inhibitors as a therapeutic strategy.
Summary:
- This review synthesizes information on radiation therapy, concurrent radiochemotherapy, and cytotoxic drugs for diffuse brain stem glioma.
- It emphasizes recent advancements in targeted therapies and antiangiogenic agents for pediatric brain tumors.
- The application of integrin inhibitors is examined as a promising avenue for treatment.
Impact:
- Provides a comprehensive overview of treatment strategies for a devastating pediatric cancer.
- Informs clinicians and researchers about the latest therapeutic developments, including novel drug classes.
- May guide future research and clinical trial design for improved outcomes in pediatric diffuse brain stem glioma.
